Toxicity induced by ciprofloxacin and enrofloxacin: oxidative stress and metabolism

References

• Abd-Elsayed A, Elsharkawy H, Sakr W. 2015. A severe interaction between tizanidine and ciprofloxacin. J Clin Anesth. 27(8):698.
   PubMedGoogle Scholar
• Abdel-Zaher AO, Afify AHM, Kamel SM, Farghaly HM, El-Osely GM, El-Awaad EAM. 2012. Involvement of glutamate, oxidative stress and inducible nitric oxide synthase in the convulsant activity of ciprofloxacin in mice. Eur J Pharmacol. 685(1-3):30–37.
   PubMed Web of Science ®Google Scholar
• Abo-EL-Sooud K, Al-Anati L. 2011. Pharmacokinetic study of flunixin and its interaction with enrofloxacin after intramuscular administration in calves. Vet World. 4(10):449–454.
   Google Scholar
• Abu-Aita NA, Ahmed KA, Mouneir SM. 2011. The protective effect of ginger and N-acetyl cysteine on ciprofloxacin-induced reproductive toxicity in male rats. J Am Sci. 7(7):741–752.
   Google Scholar
• Adefurin A, Sammons H, Jacqz-Aigrain E, Choonara I. 2011. Ciprofloxacin safety in paediatrics: a systematic review. Arch Dis Child. (9)96:874–880.
   PubMed Web of Science ®Google Scholar
• Adikwu E, Brambaifa N. 2012. Ciprofloxacin cardiotoxicity and hepatotoxicity in humans and animals. Pharmacol Pharm. 03 (02):207–213.
   Google Scholar
• Ahmed S, Ning J, Cheng G, Ahmad I, Li J, Mingyue L, Qu W, Iqbal M, Shabbir MAB, Yuan Z. 2017. Receptor-based screening assays for the detection of antibiotics residues - A review. Talanta. 166:176–186.
   PubMed Web of Science ®Google Scholar
• Ahmed AIA, van der Heijden FMMA, van den Berkmortel H, Kramers K. 2011. A man who wanted to commit suicide by hanging himself: an adverse effect of ciprofloxacin. Gen Hosp Psychiatry. 33(1):82.e5–e7.
   Google Scholar
• Ahn Y, Linder SW, Veach BT, Yan SS, Fernández AH, Pineiro SA, Cerniglia CE. 2012a. In vitro enrofloxacin binding in human fecal slurries. Regul Toxicol Pharmacol. 62(1):74–84.
   PubMedGoogle Scholar
• Ahn Y, Jung JY, Chung YH, Chae M, Jeon CO, Cerniglia CE. 2012b. In vitro analysis of the impact of enrofloxacin residues on the human intestinal microbiota using H-NMR spectroscopy. J Mol Microbiol Biotechnol. 22(5):317–325.
   PubMedGoogle Scholar
• Al-Shawi NN. 2012. Possible histological changes induced by therapeutic doses of ciprofloxacin in liver and kidney of juvenile rats. Pharmacologia. 3(9):477–480.
   Google Scholar
• Alan C, Koçoğlu H, Ersay AR, Ertung Y, Kurt HA. 2011. Unexpected severe hepatotoxicity of ciprofloxacine: two case reports. Drug Chem Toxicol. 34(2):189–191.
   PubMed Web of Science ®Google Scholar
• Aldred KJ, Kerns RJ, Osheroff N. 2014. Mechanism of quinolone action and resistance. Biochemistry. 53(10):1565–1574.
   PubMed Web of Science ®Google Scholar
• Ali AK. 2014. Peripheral neuropathy and Guillain-Barré syndrome risks associated with exposure to systemic fluoroquinolones: a pharmacovigilance analysis. Ann Epidemiol. 24(4):279–285.
   PubMed Web of Science ®Google Scholar
• Al-Omar MA. 2005. Ciprofloxacin: drug metabolism and pharmacokinetic profile. Profiles Drug Subst Excip Relat Methodol. 31:209–214.
   PubMedGoogle Scholar
• Alshammari TM, Larrat EP, Morrill HJ, Caffrey AR, Quilliam BJ, Laplante KL. 2014. Risk of hepatotoxicity associated with fluoroquinolones: a national case-control safety study. Am J Health Syst Pharm. 71(1):37–43.
   PubMed Web of Science ®Google Scholar
• Amin ML. 2013. P-glycoprotein inhibition for optimal drug delivery. Drug Target Insights. 7:27–34.
   PubMedGoogle Scholar
• Anadón A, Martinez-Larrañaga MR, Fernández MC, Díaz MJ, Bringas P. 1990. Effect of ciprofloxacin on antipyrine pharmacokinetics and metabolism in rats. Antimicrob Agents Chemother. 34(11):2148–2151.
   PubMedGoogle Scholar
• Anadón A, Martínez-Larrañaga MR. 1992. Pharmacology and toxicology of quinolones. In: Sunshine I, editor. Recent developments in therapeutic drug monitoring and clinical toxicology. 1st ed. New York (NY): Marcel Dekker, Inc.; p. 193–198.
   Google Scholar
• Anadón A, Martínez-Larrañaga MR, Velez C, Díaz MJ, Bringas P. 1992. Pharmacokinetics of norfloxacin and its N-desethyl-and oxo-metabolites in broiler chickens. Am J Vet Res. 53(11):2084–2089.
   PubMedGoogle Scholar
• Anadón A, Martı́nez-Larrañaga MR. 1999. Residues of antimicrobial drugs and feed additives in animal products: Regulatory aspects. Livest Prod Sci. 59(2-3):183–198.
   Google Scholar
• Anadón A, Martínez-Larrañaga MR, Diaz MJ, Fernández-Cruz ML, Martínez MA, Frejo MT, Martínez M, Iturbe J, Tafur M. 1999. Pharmacokinetic variables and tissue residues of enrofloxacin and ciprofloxacin in healthy pigs. Am J Vet Res. 60(11):1377–1382.
   PubMedGoogle Scholar
• Anadón A, Martínez-Larrañaga MR, Iturbe J, Martínez MA, Díaz MJ, Frejo MT, Martínez M. 2001. Pharmacokinetics and residues of ciprofloxacin and its metabolites in broiler chickens. Res Vet Sci. 71(2):101–109.
   PubMedGoogle Scholar
• Anadón A, Martínez-Larrañaga MR, Díaz MJ, Martínez MA, Frejo MT, Martínez M, Tafur M, Castellano VJ. 2002. Pharmacokinetic characteristics and tissue residues for marbofloxacin and its metabolite N-desmethyl-marbofloxacin in broiler chickens. Am J Vet Res. 63(7):927–933.
   PubMedGoogle Scholar
• Anadón A, Martínez-Larrañaga MR, Ares I, Martínez MA. 2018. Regulatory aspects for the drugs and chemicals used in food producing animals in the European Union. In: Gupta RC, editor. Veterinary toxicology basic and clinical principles. 3rd ed. San Diego (CA): Elsevier/Academic Press; p. 103–131.
   Google Scholar
• Anchordoquy JP, Anchordoquy JM, Nikoloff N, Gambaro R, Padula G, Furnus C, Seoane A. 2019. Cytotoxic and genotoxic effects induced by enrofloxacin-based antibiotic formulation Floxagen® in two experimental models of bovine cells in vitro: peripheral lymphocytes and cumulus cells. Environ Sci Pollut Res Int. 26(3):2998–3005.
   PubMedGoogle Scholar
• Andreassen V, Waagsbø B, Blix HS. 2020. Ciprofloxacin usage at a local hospital. Tidsskr nor Laegeforen. 140(14):1–6.
   Google Scholar
• Antoniou T, Gomes T, Mamdani MM, Juurlink DN. 2011. Ciprofloxacin-induced theophylline toxicity: a population-based study. Eur J Clin Pharmacol. 67(5):521–526.
   PubMed Web of Science ®Google Scholar
• Antonissen G, Devreese M, De Baere S, Martel A, Van Immerseel F, Croubels S. 2017. Impact of Fusarium mycotoxins on hepatic and intestinal mRNA expression of cytochrome P450 enzymes and drug transporters, and on the pharmacokinetics of oral enrofloxacin in broiler chickens. Food Chem Toxicol. 101:75–83.
   PubMed Web of Science ®Google Scholar
• Antonovic L, Martinez M. 2011. Role of the cytochrome P450 enzyme system in veterinary pharmacokinetics: where are we now? Where are we going? Future Med Chem. 3(7):855–879.
   PubMedGoogle Scholar
• Arabyat RM, Raisch DW, McKoy JM, Bennett CL. 2015. Fluoroquinolone-associated tendon-rupture: a summary of reports in the Food and Drug Administration's adverse event reporting system. Expert Opin Drug Saf. 14(11):1653–1660.
   PubMed Web of Science ®Google Scholar
• Arakawa H, Shirasaka Y, Haga M, Nakanishi T, Tamai I. 2012. Active intestinal absorption of fluoroquinolone antibacterial agent ciprofloxacin by organic anion transporting polypeptide, Oatp1a5. Biopharm Drug Dispos. 33(6):332–341.
   PubMed Web of Science ®Google Scholar
• Aral F, Karaçal F, Baba F. 2008. The effect of enrofloxacin on sperm quality in male mice. Res Vet Sci. 84(1):95–99.
   PubMedGoogle Scholar
• Arce JS, Romero R, Solorzano P. 2010. A case of prolonged QT interval and torsades de pointes due to ciprofloxacin. Rev Esp Cardiol. 63(1):111–112.
   PubMedGoogle Scholar
• Babaahmady E, Khosravi A. 2011. Toxicology of baytril (enrofloxacin). Afr J Pharm Pharmacol. 5(18):2042–2045.
   Google Scholar
• Babar SM. 2013. SIADH associated with ciprofloxacin. Ann Pharmacother. 47(10):1359–1363.
   PubMedGoogle Scholar
• Baboldashti NZ, Poulsen RC, Franklin SL, Thompson MS, Hulley PA. 2011. Platelet-rich plasma protects tenocytes from adverse side effects of dexamethasone and ciprofloxacin. Am J Sports Med. 39(9):1929–1935.
   PubMedGoogle Scholar
• Bacanli M, Başaran N. 2019. Importance of antibiotic residues in animal food. Food Chem Toxicol. 125:462–466.
   PubMed Web of Science ®Google Scholar
• Badal S, Her YF, Maher LJ. 3rd. 2015. Nonantibiotic effects of fluoroquinolones in mammalian cells. J Biol Chem. 290(36):22287–22297.
   PubMed Web of Science ®Google Scholar
• Balaje RM, Sidhu PK, Kaur G, Rampal S. 2013. Mutant prevention concentration and PK-PD relationships of enrofloxacin for Pasteurella multocida in buffalo calves. Res Vet Sci. 95(3):1114–1124.
   PubMedGoogle Scholar
• Baloch ZQ, Raza MA, Abbas SA, Bukhari S. 2017. Ciprofloxacin-induced hepatotoxicity in a healthy young adult. Cureus. 9(2):e1016.
   PubMedGoogle Scholar
• Barnhill AE, Brewer MT, Carlson SA. 2012. Adverse effects of antimicrobials via predictable or idiosyncratic inhibition of host mitochondrial components. Antimicrob Agents Chemother. 56(8):4046–4051.
   PubMed Web of Science ®Google Scholar
• Beberok A, Buszman E, Wrześniok D, Otręba M, Trzcionka J. 2011. Interaction between ciprofloxacin and melanin: the effect on proliferation and melanization in melanocytes. Eur J Pharmacol. 669(1-3):32–37.
   PubMed Web of Science ®Google Scholar
• Beberok A, Buszman E, Zdybel M, Pilawa B, Wrześniok D. 2010. EPR examination of free radical properties of DOPA–melanin complexes with ciprofloxacin, lomefloxacin, norfloxacin and sparfloxacin. Chem Phys Lett. 497(1-3):115–122.
   Google Scholar
• Beberok A, Wrześniok D, Rok J, Rzepka Z, Respondek M, Buszman E. 2018. Ciprofloxacin triggers the apoptosis of human triple-negative breast cancer MDA-MB-231 cells via the p53/Bax/Bcl-2 signaling pathway. Int J Oncol. 52(5):1727–1737.
   PubMed Web of Science ®Google Scholar
• Berkow R, Beers MH. 1999. The Merck manual of diagnosis and therapy. 17th ed. Whitehouse Station (NJ): Merck Research Laboratories.
   Google Scholar
• Bhutto ZA, He F, Zloh M, Yang J, Huang J, Guo T, Wang L. 2018. Use of quercetin in animal feed: effects on the P-gp expression and pharmacokinetics of orally administrated enrofloxacin in chicken. Sci Rep. 8(1):4400.
   PubMedGoogle Scholar
• Binesh A, Sivasitambaram ND, Halagowder D. 2020. Monocytes treated with ciprofloxacin and oxyLDL express myristate, priming atherosclerosis. J Biochem Mol Toxicol. 34(3):e22442.
   PubMedGoogle Scholar
• Bird ST, Etminan M, Brophy JM, Hartzema AG, Delaney JAC. 2013. Risk of acute kidney injury associated with the use of fluoroquinolones. CMAJ. 185(10):E475–482.
   PubMed Web of Science ®Google Scholar
• Bolhuis MS, Panday PN, Pranger AD, Kosterink JGW, Alffenaar JWC. 2011. Pharmacokinetic drug interactions of antimicrobial drugs: a systematic review on oxazolidinones, rifamycines, macrolides, fluoroquinolones, and beta-lactams. Pharmaceutics. 3(4):865–913.
   PubMedGoogle Scholar
• Bolon B. 2017. Mini-review: toxic tendinopathy. Toxicol Pathol. 45(7):834–837.
   PubMedGoogle Scholar
• Bonaldo G, Andriani LA, D'Annibali O, Motola D, Vaccheri A. 2019. Cardiovascular safety of macrolide and fluoroquinolone antibiotics: An analysis of the WHO database of adverse drug reactions. Pharmacoepidemiol Drug Saf. 28(11):1457–1463.
   PubMedGoogle Scholar
• Boothe DM, Boeckh A, Boothe HW. 2009. Evaluation of the distribution of enrofloxacin by circulating leukocytes to sites of inflammation in dogs. Am J Vet Res. 70(1):16–22.
   PubMedGoogle Scholar
• Bourgeois T, Delezoide A-L, Zhao W, Guimiot F, Adle-Biassette H, Durand E, Ringot M, Gallego J, Storme T, Le Guellec C, et al. 2016. Safety study of ciprofloxacin in newborn mice. Regul Toxicol Pharmacol. 74:161–169.
   PubMed Web of Science ®Google Scholar
• Brouwers EEM, Söhne M, Kuipers S, van Gorp ECM, Schellens JHM, Koks CHW, Beijnen JH, Huitema ADR. 2009. Ciprofloxacin strongly inhibits clozapine metabolism: two case reports. Clin Drug Investig. 29(1):59–63.
   PubMed Web of Science ®Google Scholar
• Cagnardi P, Ferraresi C, Lucatello L, Meucci V, Intorre L, Grilli G, Piccirillo A, Giacomelli M, Montesissa C. 2014. Enrofloxacin against Escherichia coli in turkeys: Which treatment scheme is effective? Poult Sci. 93(7):1667–1674.
   PubMedGoogle Scholar
• Chen T, Yuan J, Feng X, Wei H, Hua W. 2011. Effects of enrofloxacin on the human intestinal microbiota in vitro. Int J Antimicrob Agents. 37(6):567–571.
   PubMedGoogle Scholar
• Chrzastek K, Madej JP, Mytnik E, Wieliczko A. 2011. The influence of antibiotics on B-cell number, percentage, and distribution in the bursa of Fabricius of newly hatched chicks. Poult Sci. 90(12):2723–2729.
   PubMedGoogle Scholar
• Correia S, Poeta P, Hébraud M, Capelo JL, Igrejas G. 2017. Mechanisms of quinolone action and resistance: where do we stand? J Med Microbiol. 66(5):551–559.
   PubMed Web of Science ®Google Scholar
• Corsonello A, Abbatecola AM, Fusco S, Luciani F, Marino A, Catalano S, Maggio MG, Lattanzio F. 2015. The impact of drug interactions and polypharmacy on antimicrobial therapy in the elderly. Clin Microbiol Infect. 21(1):20–26.
   PubMed Web of Science ®Google Scholar
• Coskun D, Parlak K, Dik B, Faki HE, Bahcivan E, Yazar E, Er A. 2018. Effect of enrofloxacin on the joint fluid/blood oxidative status and organ damage markers. ARRB. 25(3):1–7.
   Google Scholar
• Cox LA, Jr, Popken DA. 2006. Quantifying potential human health impacts of animal antibiotic use: enrofloxacin and macrolides in chickens. Risk Anal. 26(1):135–146.
   PubMedGoogle Scholar
• Cox SK, Cottrell MB, Smith L, Papich MG, Frazier DL, Bartges J. 2004. Allometric analysis of ciprofloxacin and enrofloxacin pharmacokinetics across species. J Vet Pharmacol Ther. 27(3):139–146.
   PubMedGoogle Scholar
• Cui Y, Liu B, Xie J, Xu P, Zhang Y, Ming J. 2014. Effect of enrofloxacin and emodin on heat-shock proteins’ expression in hepatic cells of grass carp (Ctenopharyngodon idellus). Aquacult Int. (3)22:1067–1077.
   Google Scholar
• Dahmke H, Jetter A, Kupferschmidt H, Kullak-Ublick GA, Weiler S. 2017. Co-administration of tizanidine and ciprofloxacin: a retrospective analysis of the WHO pharmacovigilance database. Clin Ther. 39(8):E1.
   PubMedGoogle Scholar
• Dai XC, Yang XX, Ma L, Tang GM, Pan YY, Hu HL. 2020. Relationship between fluoroquinolones and the risk of aortic diseases: a meta-analysis of observational studies. BMC Cardiovasc Disord. 20(1):49.
   PubMedGoogle Scholar
• Dalhoff A. 2012. Global fluoroquinolone resistance epidemiology and implications for clinical use. Interdiscip Perspect Infect Dis. 2012:1–37.
   Google Scholar
• Daundkar PS, Vemu B, Dumka VK, Sharma SK. 2015. Pharmacokinetic-pharmacodynamic integration of enrofloxacin and its metabolite ciprofloxacin in buffalo calves. Vet Med Sci. 1(2):63–71.
   PubMedGoogle Scholar
• De Schryver N, Wittebole X, Van den Bergh P, Haufroid V, Goffin E, Hantson P. 2015. Severe rhabdomyolysis associated with simvastatin and role of ciprofloxacin and amlodipine coadministration. Case Rep Nephrol. 2015:761393.
   PubMedGoogle Scholar
• Deb U, Ray S, Biswas S. 2019. Topical ciprofloxacin induced ocular toxicity: case report. Int J Basic Clin Pharmacol. 8(11):2570–2572.
   Google Scholar
• DeGorter MK, Xia CQ, Yang JJ, Kim RB. 2012. Drug transporters in drug efficacy and toxicity. Annu Rev Pharmacol Toxicol. 52:249–273.
   PubMed Web of Science ®Google Scholar
• Devreese M, Antonissen G, De Baere S, De Backer P, Croubels S. 2014. Effect of administration route and dose escalation on plasma and intestinal concentrations of enrofloxacin and ciprofloxacin in broiler chickens. BMC Vet Res. 10:289.
   PubMedGoogle Scholar
• Dionísio R, Daniel D, de Alkimin GD, Nunes B. 2020. Multi-parametric analysis of ciprofloxacin toxicity at ecologically relevant levels: Short- and long-term effects on Daphnia magna . Environ Toxicol Pharmacol. 74:103295.
   PubMed Web of Science ®Google Scholar
• Divers SJ, Stahl SJ. 2018. Mader's reptile and amphibian medicine and surgery-e-book, Elsevier Health Sciences, Amsterdam.
   Google Scholar
• Dogan Z, Elbe H, Taslidere E, Soysal H, Cetin A, Demirtas S. 2017. Effects of ciprofloxacin on fetal rat liver during pregnancy and protective effects of quercetin. Biotech Histochem. 92(7):481–486.
   PubMed Web of Science ®Google Scholar
• Dogan Z, Cetin A, Elibol E, Vardi N, Turkoz Y. 2019. Effects of ciprofloxacin and quercetin on fetal brain development: a biochemical and histopathological study. J Matern Fetal Neonatal Med. 32(11):1783–1791.
   PubMed Web of Science ®Google Scholar
• Donaldson D, Matas Riera M, Holloway A, Beltran E, Barnett KC. 2014. Contralateral optic neuropathy and retinopathy associated with visual and afferent pupillomotor dysfunction following enucleation in six cats. Vet Ophthalmol. 17(5):373–384.
   PubMedGoogle Scholar
• Donkor ES, Newman MJ, Tay SCK, Dayie NTKD, Bannerman E, Olu-Taiwo M. 2011. Investigation into the risk of exposure to antibiotic residues contaminating meat and egg in Ghana. Food Control. 22(6):869–873.
   Web of Science ®Google Scholar
• Doyle HE. 2010. Tendinopathy resulting from the use of fluoroquinolones: Managing risks. JAAPA. 23(12):18–21.
   PubMedGoogle Scholar
• EC (European Commission). 2009. Regulation (EC) No 470/2009 of the European Parliament and of the Council of 6 May 2009 laying down Community procedures for the establishment of residue limits of pharmacologically active substances in foodstuffs of animal origin, repealing Council Regulation (EEC) No 2377/90 and amending Directive 2001/82/EC of the European Parliament and of the Council and Regulation (EC) No 726/2004 of the European Parliament and of the Council. Off J Eur Union L. 152:11–22.
   Google Scholar
• EC (European Commission). 2010. Commission Regulation (EU) no. 37/2010 of 22 December 2009 on pharmacologically active substances and their classification regarding maximum residue limits in foodstuffs of animal origin (Text with EEA relevance). Off J Eur Union. L15:1–72.
   Google Scholar
• EC 2014. Commission implementing decision of 28.2.2014 concerning, in the framework of Article 35 of Directive 2001/82/EC of the European Parliament and of the Council, the marketing authorisations for veterinary medicinal products containing “enrofloxacin” to be administered via the drinking water to chickens and/or turkeys. Brussels, 28.2.2014. C(2014) 1484 final.
   Google Scholar
• EFSA (European Food Safety Authority). 2017. EMA Committee for Medicinal Products for Veterinary Use (CVMP) and EFSA Panel on Biological Hazards (BIOHAZ). EMA and EFSA Joint Scientific Opinion on measures to reduce the need to use antimicrobial agents in animal husbandry in the European Union, and the resulting impacts on food safety (RONAFA). 15(1):e04666.
   Google Scholar
• Eisele S, Garbe E, Zeitz M, Schneider T, Somasundaram R. 2009. Ciprofloxacin-related acute severe myalgia necessitating emergency care treatment: a case report and review of the literature. Int J Clin Pharmacol Ther. 47(3):165–168.
   PubMedGoogle Scholar
• El-Daly AAA. 2013. Ultrastructural study on the effects of green tea extract on enerofloxacin-induced kidney injury in rats. Glob J Pharmacol. 7(4):365–376.
   Google Scholar
• Elamaran A, Hariharan P, Ramesh S, Vairamuthu S. 2015. Enrofloxacin induced oxidative stress and its amelioration with antioxidants in liver homogenates of broilers. Indian J Vet Anim Sci. 11(2):124–128.
   Google Scholar
• Elbe H, Dogan Z, Taslidere E, Cetin A, Turkoz Y. 2016. Beneficial effects of quercetin on renal injury and oxidative stress caused by ciprofloxacin in rats: a histological and biochemical study. Hum Exp Toxicol. 35(3):276–281.
   PubMed Web of Science ®Google Scholar
• Ellerbrock RE, Canisso IF, Roady PJ, Rothrock LT, Zhong L, Wilkins P, Dirikolu L, Lima FS, Honoroto J. 2019. Diffusion of enrofloxacin to pregnancy fluids and effects on fetal cartilage after intravenous administration to late pregnant mares. Equine Vet J. 51(4):544–551.
   PubMedGoogle Scholar
• Ellerbrock RE, Curcio BR, Zhong L, Honoroto J, Wilkins P, Lima FS, Giguere S, Canisso IF. 2020. Pharmacokinetics of intravenous and oral administration of enrofloxacin to the late‐term pregnant and non‐pregnant mares. Equine Vet J. 52(3):464–470.
   PubMedGoogle Scholar
• EMA 2010. Opinion following an Article 35 referral for all veterinary medicinal products containing quinolones including fluoroquinolones intended for use in food-producing species. Committee for medicinal products for veterinary use (CVMP). European Medicines Agency. EMA/186029/2010 [accessed 2021 Jul 30].
   Google Scholar
• EMEA (European Medicines Evaluation Agency). 2007. Public statement on the use of (fluoro)quinolones in food-producing animals in the European Union: development of resistance and impact on human and animal health. Committee for Medicinal Products for Veterinary Use (CVMP). European Medicines Agency. EMEA/CVMP/SAGAM/184651/2005. [accessed 2021 Jul 30].
   Google Scholar
• Endt K, Maier L, Käppeli R, Barthel M, Misselwitz B, Kremer M, Hardt WD. 2012. Peroral ciprofloxacin therapy impairs the generation of a protective immune response in a mouse model for Salmonella enterica serovar Typhimurium diarrhea, while parenteral ceftriaxone therapy does not. Antimicrob Agents Chemother. 56(5):2295–2304.
   PubMedGoogle Scholar
• Ershov E, Bellaiche M, Hanji V, Soback S, Gips M, Shlosberg A. 2001. Interaction of fluoroquinolones and certain ionophores in broilers: effect on blood levels and hepatic cytochrome P450 monooxygenase activity. Drug Metabol Drug Interact. 18(3-4):209–219.
   PubMedGoogle Scholar
• Etminan M, Forooghian F, Brophy JM, Bird ST, Maberley D. 2012. Oral fluoroquinolones and the risk of retinal detachment. JAMA. 307(13):1414–1419.
   PubMed Web of Science ®Google Scholar
• Fang X, Zhou J, Liu X. 2016. Pharmacokinetics of enrofloxacin in snakehead fish, Channa argus. J Vet Pharmacol Ther. 39(2):209–212.
   PubMedGoogle Scholar
• FDA (US Food and Drug Administration). 2021. CFR Code of Federal Regulations Title 21 subpart B: Specific tolerances for residues of approved and conditionally approved new animal drugs. U.S. Food and Drug Administration. [accessed 2021 Oct 19].
   Google Scholar
• Finch A, Pillans P. 2014. P-glycoprotein and its role in drug-drug interactions. Aust Prescr. 37(4):137–139.
   Google Scholar
• Ford MM, Dubielzig RR, Giuliano EA, Moore CP, Narfström KL. 2007. Ocular and systemic manifestations after oral administration of a high dose of enrofloxacin in cats. Am J Vet Res. 68(2):190–202.
   PubMedGoogle Scholar
• Fountoulakis N, Khafizova L, Logothetis M, Fanti G, Papadakis JA. 2013. Case report of rhabdomyolysis possibly associated to the interaction of ciprofloxacin with simvastatin. Hell J Atherosclerosis. 1(1):65–67.
   Google Scholar
• Franciolli ALR, Cordeiro BM, da Fonseca ET, Rodrigues MN, Sarmento CAP, Ambrosio CE, de Carvalho AF, Miglino MA, Silva LA. 2011. Characteristics of the equine embryo and fetus from days 15 to 107 of pregnancy. Theriogenology. 76(5):819–832.
   PubMedGoogle Scholar
• Francis JK, Higgins E. 2014. Permanent peripheral neuropathy: a case report on a rare but serious debilitating side-effect of fluoroquinolone administration. J Investig Med High Impact Case Rep. 2(3):2324709614545225.
   Google Scholar
• Fromenty B. 2020. Alteration of mitochondrial DNA homeostasis in drug-induced liver injury. Food Chem Toxicol. 135:110916.
   PubMedGoogle Scholar
• Frommeyer G, Eckardt L. 2016. Drug-induced proarrhythmia: risk factors and electrophysiological mechanisms. Nat Rev Cardiol. 13(1):36–47.
   PubMedGoogle Scholar
• Fu G, Zhou C, Wang Y, Fang W, Zhou J, Zhao S, Ma L. 2016. Effects of inducers of cytochrome P450s on enrofloxacin N-deethylation in crucian carp Carassius auratus gibelio. Environ Toxicol Pharmacol. 46:188–193.
   PubMedGoogle Scholar
• Garg V, Shen J, Li C, Agarwal S, Gebre A, Robertson S, Huang J, Han L, Jiang L, Stephan K, et al. 2019. Pharmacokinetic and Drug-Drug Interaction Profiles of the Combination of Tezacaftor/Ivacaftor. Clin Transl Sci. 12(3):267–275.
   PubMed Web of Science ®Google Scholar
• Gbylik-Sikorska M, Posyniak A, Śniegocki T, Sell B, Gajda A, Tomczyk G, Żmudzki J. 2016a. Effect of doxycycline concentrations in chicken tissues as a consequence of permanent exposure to enrofloxacin traces in drinking water. J Vet Res. 60(3):293–299.
   Google Scholar
• Gbylik-Sikorska M, Posyniak A, Sniegocki T, Sell B, Gajda A, Sawicka A, Olszewska-Tomczyk M, Bladek T, Tomczyk G, Zmudzki J. 2016b. Influence of enrofloxacin traces in drinking water to doxycycline tissue pharmacokinetics in healthy and infected by Mycoplasma gallisepticum broiler chickens. Food Chem Toxicol. 90:123–129.
   PubMedGoogle Scholar
• Gbylik-Sikorska M, Gajda A, Posyniak A. 2018. Pharmacokinetic depletion phase of doxycycline in healthy and Mycoplasma gallisepticum-infected chicken broilers after coadministration of enrofloxacin traces. J Vet Pharmacol Ther. 41(1):166–169.
   PubMedGoogle Scholar
• Gessner A, König J, Fromm MF. 2019. Clinical aspects of transporter-mediated drug-drug interactions. Clin Pharmacol Ther. 105(6):1386–1394.
   PubMed Web of Science ®Google Scholar
• Giguère S, Prescott JF, Dowling PM. 2013. Antimicrobial Therapy in Veterinary Medicine. 5th ed. John Wiley and Sons, Inc.
   Google Scholar
• Goetting V, Lee KA, Tell LA. 2011. Pharmacokinetics of veterinary drugs in laying hens and residues in eggs: a review of the literature. J Vet Pharmacol Ther. 34(6):521–556.
   PubMed Web of Science ®Google Scholar
• Goldie FC, Brogan A, Boyle JG. 2016. Ciprofloxacin and statin interaction: a cautionary tale of rhabdomyolysis. BMJ Case Rep. 2016:bcr2016216048.
   PubMedGoogle Scholar
• Golomb BA, Koslik HJ, Redd AJ. 2015. Fluoroquinolone-induced serious, persistent, multisymptom adverse effects. BMJ Case Rep. 2015:bcr:bcr2015209821.
   PubMedGoogle Scholar
• Gorla N, Ovando HG, Larripa I. 1999. Chromosomal aberrations in human lymphocytes exposed in vitro to enrofloxacin and ciprofloxacin. Toxicol Lett. 104(1-2):43–48.
   PubMedGoogle Scholar
• Gouvêa R, dos Santos FF, de Aquino MHC, de A Pereira VL. 2015. Fluoroquinolones in industrial poultry production, bacterial resistance and food residues: a review. Rev Bras Cienc Avic. 17(1):1–10.
   Google Scholar
• Granfors MT, Backman JT, Neuvonen M, Neuvonen PJ. 2004. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2–mediated presystemic metabolism. Clin Pharmacol Ther. 76(6):598–606.
   PubMed Web of Science ®Google Scholar
• Grzybowski A, Zülsdorff M, Wilhelm H, Tonagel F. 2015. Toxic optic neuropathies: an updated review. Acta Ophthalmol. 93(5):402–410.
   PubMed Web of Science ®Google Scholar
• Guo J, Zhu X, Badawy S, Ihsan A, Liu Z, Xie C, Wang X. 2021. Metabolism and mechanism of human cytochrome P450 enzyme 1A2. Curr Drug Metab. 22(1):40–49.
   PubMed Web of Science ®Google Scholar
• Guo M, Bughio S, Sun Y, Zhan Y, Dong L, Dai X, Wang L. 2013. Age-related P-glycoprotein expression in the intestine and affecting the pharmacokinetics of orally administered enrofloxacin in broilers. PloS One. 8(9):e74150.
   PubMedGoogle Scholar
• Guo M, Sun Y, Zhang Y, Bughio S, Dai X, Ren W, Wang L. 2014. E. coli infection modulates the pharmacokinetics of oral enrofloxacin by targeting P-glycoprotein in small intestine and CYP450 3A in liver and kidney of broilers. PLoS One. 9(1):e87781.
   PubMedGoogle Scholar
• Guo M, Dai X, Hu D, Zhang Y, Sun Y, Ren W, Wang L. 2016a. Potential pharmacokinetic effect of rifampicin on enrofloxacin in broilers: roles of P-glycoprotein and BCRP induction by rifampicin. Poult Sci. 95(9):2129–2135.
   PubMedGoogle Scholar
• Guo T, Huang J, Zhang H, Dong L, Guo D, Guo L, He F, Bhutto ZA, Wang L. 2016b. Abcb1 in Pigs: Molecular cloning, tissues distribution, functional analysis, and its effect on pharmacokinetics of enrofloxacin. Sci Rep. 6(32244):32244.
   PubMedGoogle Scholar
• Gürbay A, Gonthier B, Signorini-Allibe N, Barret L, Favier A, Hıncal F. 2006. Ciprofloxacin-induced DNA damage in primary culture of rat astrocytes and protection by vitamin E. Neurotoxicology. 27(1):6–10.
   PubMedGoogle Scholar
• Gürbay A, Gonthier B, Barret L, Favier A, Hıncal F. 2007. Cytotoxic effect of ciprofloxacin in primary culture of rat astrocytes and protection by vitamin E. Toxicology. 229(1-2):54–61.
   PubMed Web of Science ®Google Scholar
• Gürbay A, Gonthier B, Daveloose D, Barret L, Favier A, Hıncal F. 2019. Ciprofloxacin-induces free radical production in rat cerebral microsomes. Free Radic Res. 53(4):397–404.
   PubMed Web of Science ®Google Scholar
• Hall MM, Finnoff JT, Smith J. 2011. Musculoskeletal complications of fluoroquinolones: guidelines and precautions for usage in the athletic population. PM&R. 3(2):132–142.
   Google Scholar
• Hangas A, Aasumets K, Kekäläinen NJ, Paloheinä M, Pohjoismäki JL, Gerhold JM, Goffart S. 2018. Ciprofloxacin impairs mitochondrial DNA replication initiation through inhibition of topoisomerase 2. Nucleic Acids Res. 46(18):9625–9636.
   PubMed Web of Science ®Google Scholar
• Harada K, Usui M, Asai T. 2014. Application of enrofloxacin and orbifloxacin disks approved in Japan for susceptibility testing of representative veterinary respiratory pathogens. J Vet Med Sci. 76(10):1427–1430.
   PubMedGoogle Scholar
• Haritova A, Urumova V, Lutckanov M, Petrov V, Lashev L. 2011. Pharmacokinetic-pharmacodynamic indices of enrofloxacin in Escherichia coli O78/H12 infected chickens. Food Chem Toxicol. 49(7):1530–1536.
   PubMedGoogle Scholar
• Haritova A, Dimitrova D, Dinev T, Moutafchieva R, Lashev L. 2013. Comparative pharmacokinetics of enrofloxacin, danofloxacin, and marbofloxacin after intravenous and oral administration in Japanese quail (Coturnix coturnix japonica). J Avian Med Surg. 27(1):23–31.
   PubMedGoogle Scholar
• Hines LE, Murphy JE. 2011. Potentially harmful drug-drug interactions in the elderly: a review. Am J Geriatr Pharmacother. 9(6):364–377.
   PubMed Web of Science ®Google Scholar
• Hori K, Yamakawa K, Yoshida N, Ohnishi K, Kawakami J. 2012. Detection of fluoroquinolone-induced tendon disorders using a hospital database in Japan . Pharmacoepidemiol Drug Saf. 21(8):886–889.
   PubMed Web of Science ®Google Scholar
• Hosohata K. 2016. Role of oxidative stress in drug-induced kidney injury. IJMS. 17(11):1826.
   Google Scholar
• Hu HF, Gao ZX, Cheng YY. 2010. Inhibition of CYP3A mRNA and protein expression, and enzymatic activity, by enrofloxacin in chickens. J Vet Pharmacol Ther. 33(6):546–550.
   PubMedGoogle Scholar
• Hu SX, Mazur CA, Feenstra KL, Lorenz JK, Merritt DA. 2016. Assessment of inhibition of porcine hepatic cytochrome P450 enzymes by 48 commercial drugs. Vet J. 211:26–31.
   PubMed Web of Science ®Google Scholar
• Hu X, Li XC, Sun BB, Fang WH, Zhou S, Hu LL, Zhou JF. 2012. Effects of enrofloxacin on cytochromes P4501A and P4503A in Carassius auratus gibelio (crucian carp). J Vet Pharmacol Ther. 35(3):216–223.
   PubMedGoogle Scholar
• Hwang YH, Kim MS, Song IB, Lim JH, Park BK, Yun HI. 2009. Altered pharmacokinetics of enrofloxacin in experimental models of hepatic and renal impairment. Vet Res Commun. 33(5):481–487.
   PubMedGoogle Scholar
• Hwang YH, Yang HJ, Kim DG, Ma JY. 2017. Inhibitory effects of multiple-dose treatment with baicalein on the pharmacokinetics of ciprofloxacin in rats. Phytother Res. 31(1):69–74.
   PubMedGoogle Scholar
• Ibrahim IG, Yarsan E. 2011. Enrofloxacin drug induced reactive oxygen species. Res Opin Anim Vet Sci. 1(8):489–491.
   Google Scholar
• Ilgin S, Can OD, Atli O, Ucel UI, Sener E, Guven I. 2015. Ciprofloxacin-induced neurotoxicity: evaluation of possible underlying mechanisms. Toxicol Mech Methods. 25(5):374–381.
   PubMed Web of Science ®Google Scholar
• Jaber DF, Jallad MAN, Abdelnoor AM. 2017. The effect of ciprofloxacin on the growth of B16F10 melanoma cells. J Cancer Res Ther. 13(6):956–960.
   PubMedGoogle Scholar
• Jackson MA, Schutze GE. 2016. Committee on Infectious Diseases. 2016. The use of systemic and topical fluoroquinolones. Pediatrics. Am Acad Pediatr. 138(5):e20162706.
   PubMedGoogle Scholar
• Kaleagasioglu F, Olcay E. 2012. Fluoroquinolone-induced tendinopathy: etiology and preventive measures. Tohoku J Exp Med. 226(4):251–258.
   PubMed Web of Science ®Google Scholar
• Kalpana S, Aggarwal M, Rao GS, Malik JK. 2012. Effects of aflatoxin B1 on tissue residues of enrofloxacin and its metabolite ciprofloxacin in broiler chickens. Environ Toxicol Pharmacol. 33(2):121–126.
   PubMedGoogle Scholar
• Kang J, Hossain MA, Park HC, Kim Y, Lee KJ, Park SW. 2019. Pharmacokinetic and pharmacodynamic integration of enrofloxacin against Salmonella Enteritidis after administering to broiler chicken by per-oral and intravenous routes. J Vet Sci. 20(2):e15.
   PubMed Web of Science ®Google Scholar
• Karademir U, Boyacioglu M, Kum C, Sekkin S. 2015. Comparative pharmacokinetics of enrofloxacin, danofloxacin and marbofloxacin following intramuscular administration in sheep. Small Rumin Res. 133:108–111.
   Web of Science ®Google Scholar
• Kamath A. 2013. Fluoroquinolone induced neurotoxicity: A review. J Adv Pharm Edu & Res. 3(1):72–75.
   Google Scholar
• Karriker LA, Coetzee JF, Friendship RM, Apley MD. 2019. Drug pharmacology, therapy, and prophylaxis. In: Zimmerman JJ, Karriker LA, Ramirez A, Schwartz KJ, Stevenson GW, Zhang J, editors. Diseases of swine. 11th ed. Hoboken (NJ): Wiley; p. 158–170.
   Google Scholar
• Khaki A, Heidari M, Novin MG, Khaki AA. 2008. Adverse effects of ciprofloxacin on testis apoptosis and sperm parameters in rats. Iran J Reprod Med. 6(2):71–76.
   Google Scholar
• Khan M, Ortega LM, Bagwan N, Nayer A. 2015a. Crystal-induced acute kidney injury due to ciprofloxacin. J Nephropathol. 4(1):29–31.
   PubMedGoogle Scholar
• Khan GJ, Khan RA, Majeed I, Siddiqui FA, Khan S. 2015b. Ciprofloxacin; the frequent use in poultry and its consequences on human health. TPMJ. 22(01):001–005.
   Google Scholar
• Khan AM, Rampal S, Sood NK. 2017. Effect of repeated oral administration of levofloxacin, enrofloxacin, and meloxicam on antioxidant parameters and lipid peroxidation in rabbits. Hum Exp Toxicol. 36(1):42–50.
   PubMed Web of Science ®Google Scholar
• Khan AM, Rampal S, Sood NK. 2018. Effect of levofloxacin, pazufloxacin, enrofloxacin, and meloxicam on the immunolocalization of ABCG-2 transporter protein in rabbit retina. Environ Sci Pollut Res Int. 25(9):8853–8860.
   PubMedGoogle Scholar
• Khandelwal V, Pradhan N, Mathu P, Jhawa S, Singh AP. 2020. Enrofloxacin poisoning in humans–a rare case report. Indian J Forensic Med Toxicol. 14(3):76–78.
   Google Scholar
• Khazaeil K, Mazaheri Y, Hashemitabar M, Najafzadeh H, Morovvati H, Ghadrdan AR. 2012. Enrofloxacin effect on histomorphologic and histomorphometric structure of lamb articular cartilage. Glob Vet. 9(4):447–453.
   Google Scholar
• Kireewan S, Suanpairintr N. 2017. Comparative in vitro killing activities of enrofloxacin when used alone and in combination with doxycycline against E. coli isolated from dogs and cats. Thai J Vet Med. 47(2):217–224.
   Google Scholar
• Klaudia C, Alina W. 2015. The influence of enrofloxacin, florfenicol, ceftiofur and E. coli LPS interaction on T and B cells subset in chicks. Vet Res Commun. 39(1):53–60.
   PubMedGoogle Scholar
• Kloskowski T, Gurtowska N, Nowak M, Joachimiak R, Bajek A, Olkowska J, Drewa T. 2011. The influence of ciprofloxacin on viability of A549, HepG2, A375.S2, B16 and C6 cell lines in vitro. Acta Pol Pharm. 68(6):859–865.
   PubMedGoogle Scholar
• Kloskowski T, Gurtowska N, Olkowska J, Nowak JM, Adamowicz J, Tworkiewicz J, Dębski R, Grzanka A, Drewa T. 2012. Ciprofloxacin is a potential topoisomerase II inhibitor for the treatment of of NSCLC. Int J Oncol. 41(6):1943–1949.
   PubMedGoogle Scholar
• Kommalapati A, Wallam S, Tella SH, Qureshi ZP, Bennett CL. 2018. Fluoroquinolone-associated suicide. Eur J Intern Med. 55:e21–e22.
   PubMedGoogle Scholar
• Kowalska J, Banach K, Beberok A, Rok J, Rzepka Z, Wrześniok D. 2021. The biochemical and molecular analysis of changes in melanogenesis induced by UVA-activated fluoroquinolones. In vitro study on human normal melanocytes. Cells. 10(11):2900.
   Google Scholar
• Kumar PS, Arivuchelvan A, Jagadeeswaran A, Punniamurthy N, Selvaraj P, Jagatheesan PNR, Mekala P. 2015. Pharmacokinetics of enrofloxacin in Emu (Dromaius novaehollandiae) birds after intravenous and oral bolus administration. Proc Natl Acad Sci, India, Sect B Biol Sci. 85(3):845–851.
   Google Scholar
• Kuo SC, Chen YT, Lee YT, Fan NW, Chen SJ, Li SY, Liu CJ, Chen TL, Chen TJ, Fung CP. 2014. Association between recent use of fluoroquinolones and rhegmatogenous retinal detachment: a population-based cohort study. Clin Infect Dis. 58(2):197–203.
   PubMed Web of Science ®Google Scholar
• Landersdorfer CB, Kirkpatrick CMJ, Kinzig M, Bulitta JB, Holzgrabe U, Jaehde U, Reiter A, Naber KG, Rodamer M, Sörgel F. 2010. Competitive inhibition of renal tubular secretion of ciprofloxacin and metabolite by probenecid. Br J Clin Pharmacol. 69(2):167–178.
   PubMed Web of Science ®Google Scholar
• Lang TR, Cook J, Rio E, Gaida JE. 2017. What tendon pathology is seen on imaging in people who have taken fluoroquinolones? A systematic review. Fundam Clin Pharmacol. 31(1):4–16.
   PubMed Web of Science ®Google Scholar
• Lappin MR, Blondeau J, Boothe D, Breitschwerdt EB, Guardabassi L, Lloyd DH, Papich MG, Rankin SC, Sykes JE, Turnidge J, et al. 2017. Antimicrobial use guidelines for treatment of respiratory tract disease in dogs and cats: antimicrobial guidelines working group of the international society for companion animal infectious diseases. J Vet Intern Med. 31(2):279–294.
   PubMedGoogle Scholar
• LaSalvia EA, Domek GJ, Gitlin DF. 2010. Fluoroquinolone-induced suicidal ideation. Gen Hosp Psychiatry. 32(1):108–110.
   PubMedGoogle Scholar
• Lashev LD, Dimitrova DJ, Milanova A, Moutafchieva RG. 2015. Pharmacokinetics of enrofloxacin and marbofloxacin in Japanese quails and common pheasants. Br Poult Sci. 56(2):255–261.
   PubMed Web of Science ®Google Scholar
• Lee CC, Lee MTG, Chen YS, Lee SH, Chen YS, Chen SC, Chang SC. 2015. Risk of aortic dissection and aortic aneurysm in patients taking oral fluoroquinolone. JAMA Intern Med. 175(11):1839–1847.
   PubMed Web of Science ®Google Scholar
• LeMaire SA, Zhang L, Luo W, Ren P, Azares AR, Wang Y, Zhang C, Coselli JS, Shen YH. 2018. Effect of ciprofloxacin on susceptibility to aortic dissection and rupture in mice. JAMA Surg. 153(9):e181804.
   PubMed Web of Science ®Google Scholar
• Lewis T, Cook J. 2014. Fluoroquinolones and tendinopathy: a guide for athletes and sports clinicians and a systematic review of the literature. J Athl Train. 49(3):422–427.
   PubMed Web of Science ®Google Scholar
• Li Y, Hu Y, Ai X, Qiu J, Wang X. 2015. Acute and sub-acute effects of enrofloxacin on the earthworm species Eisenia fetida in an artificial soil substrate. Eur J Soil Biol. 66:19–23.
   Google Scholar
• Li J, Hao H, Cheng G, Wang X, Ahmed S, Shabbir MAB, Liu Z, Dai M, Yuan Z. 2017. The effects of different enrofloxacin dosages on clinical efficacy and resistance development in chickens experimentally infected with Salmonella Typhimurium. Sci Rep. 7(1):11676.
   PubMedGoogle Scholar
• Li Y, Mou Y, Thunders M, Wu Y, Ai X, Zhou X, Qiu J. 2018a. Effects of enrofloxacin on antioxidant system, microsomal enzymatic activity and proteomics in porcine liver. J Vet Pharmacol Ther. 41(4):562–571.
   PubMedGoogle Scholar
• Li Y, Tang H, Hu Y, Wang X, Ai X, Tang L, Matthew C, Cavanagh J, Qiu J. 2016. Enrofloxacin at environmentally relevant concentrations enhances uptake and toxicity of cadmium in the earthworm Eisenia fetida in farm soils. J Hazard Mater. 308:312–320.
   PubMed Web of Science ®Google Scholar
• Li Y, Jiang M, Thunders M, Ai X, Qiu J. 2018b. Effect of enrofloxacin and roxarsone on CYP450s in pig. Res Vet Sci. 117:97–98.
   PubMedGoogle Scholar
• Licata A, Randazzo C, Morreale I, Butera G, D'Alessandro N, Craxì A. 2012. Fluoroquinolone-induced liver injury: three new cases and a review of the literature. Eur J Clin Pharmacol. 68(5):525–532.
   PubMedGoogle Scholar
• Liguori I, Russo G, Curcio F, Bulli G, Aran L, Della-Morte D, Gargiulo G, Testa G, Cacciatore F, Bonaduce D, et al. 2018. Oxidative stress, aging, and diseases. Clin Interv Aging. 13:757–772.
   PubMed Web of Science ®Google Scholar
• Lim S, Hossain MA, Park J, Choi SH, Kim G. 2008. The effects of enrofloxacin on canine tendon cells and chondrocytes proliferation in vitro. Vet Res Commun. 32(3):243–253.
   PubMedGoogle Scholar
• Liu A, Wu Q, Guo J, Ares I, Rodríguez JL, Martínez-Larrañaga MR, Yuan Z, Anadón A, Wang X, Martínez MA. 2019. Statins: adverse reactions, oxidative stress and metabolic interactions. Pharmacol Ther. 195:54–84.
   PubMed Web of Science ®Google Scholar
• Liu B, Cui Y, Brown PB, Ge X, Xie J, Xu P. 2015. Cytotoxic effects and apoptosis induction of enrofloxacin in hepatic cell line of grass carp (Ctenopharyngodon idellus). Fish Shellfish Immunol. 47(2):639–644.
   PubMedGoogle Scholar
• Locuson CW, Williams P, Adcock JM, Daniels JS. 2016. Evaluation of tizanidine as a marker of canine CYP1A2 activity. J Vet Pharmacol Ther. 39(2):122–130.
   PubMed Web of Science ®Google Scholar
• López-Cadenas C, Sierra-Vega M, García-Vieitez JJ, Diez-Liébana MJ, Sahagún-Prieto A, Fernández-Martínez N. 2013. Enrofloxacin: pharmacokinetics and metabolism in domestic animal species. Curr Drug Metab. 14(10):1042–1058.
   PubMedGoogle Scholar
• Lu X, Li Y, Thunders M, Matthew C, Wang X, Ai X, Zhou X, Qiu J. 2018. Effect of enrofloxacin on the proteome of earthworms. Sci Total Environ. 616-617:531–542.
   PubMedGoogle Scholar
• Ma YJ, Jiang DQ, Meng JX, Li MX, Zhao HH, Wang Y, Wang LQ. 2016. Theophylline: a review of population pharmacokinetic analyses. J Clin Pharm Ther. 41(6):594–601.
   PubMed Web of Science ®Google Scholar
• Machuca J, Briales A, Labrador G, Díaz-de-Alba P, López-Rojas R, Docobo-Pérez F, Martínez-Martínez L, Rodríguez-Baño J, Pachón ME, Pascual A, et al. 2014. Interplay between plasmid-mediated and chromosomal-mediated fluoroquinolone resistance and bacterial fitness in Escherichia coli. J Antimicrob Chemother. 69(12):3203–3215.
   PubMed Web of Science ®Google Scholar
• Maftuch Aziz K, Eslfitri D, Sanoesi E, Prihanto AA. 2017. Enrofloxacin stimulates cell death in several tissues of vannamei shrimp (Litopenaeus vannamei). Comp Clin Pathol. 26:249–254.
   Google Scholar
• Mancano MA. 2014. Ciprofloxacin-induced syndrome of inappropriate antidiuretic hormone; anaphylactic shock due to thrombolytic administration; hydroxychloroquine-induced QT-interval prolongation; complex regional pain syndrome after tetanus toxoid injection. Hosp Pharm. 49(4):329–333.
   PubMedGoogle Scholar
• Manikandan P, Nagini S. 2018. Cytochrome P450 structure, function and clinical significance: a review. Curr Drug Targets. 19(1):38–54.
   PubMed Web of Science ®Google Scholar
• Marsousi N, Desmeules JA, Rudaz S, Daali Y. 2018. Prediction of drug-drug interactions using physiologically-based pharmacokinetic models of CYP450 modulators included in Simcyp software. Biopharm Drug Dispos. 39(1):3–17.
   PubMedGoogle Scholar
• McDonald EM, Ram FSF, Patel DV, McGhee CNJ. 2014. Topical antibiotics for the management of bacterial keratitis: an evidence-based review of high quality randomised controlled trials. Br J Ophthalmol. 98(11):1470–1477.
   PubMedGoogle Scholar
• Mekala P, Jagadeeswaran A, Arivuchelvan A, Senthilkumar P, Nanjappan K, Krishnamurthy TRG. 2014. Pharmacokinetics of enrofloxacin after single intravenous and oral bolus administration in broiler chicken. Int J Adv Vet Sci Technol. 3(1):99–105.
   Google Scholar
• Mekala P, Jagadeeswaran A, Arivuchelvan A, Kumar PS, Nanjappan K, Murthy TRGK. 2015. Interaction kinetics of enrofloxacin with hydrated sodium calcium aluminosilicate-a toxin binder in broiler chicken authors. World J Pharm Res. 4(5):1867–1882.
   Google Scholar
• Meyer JM, Proctor G, Cummings MA, Dardashti LJ, Stahl SM. 2016. Ciprofloxacin and Clozapine: A Potentially Fatal but Underappreciated Interaction. Case Rep Psychiatry. 2016:5606098.
   PubMedGoogle Scholar
• Michalak K, Sobolewska-Włodarczyk A, Włodarczyk M, Sobolewska J, Woźniak P, Sobolewski B. 2017. Treatment of the fluoroquinolone-associated disability: the pathobiochemical implications. Oxid Med Cell Longev. 2017:8023935.
   PubMed Web of Science ®Google Scholar
• Mitchell MA. 2006. Enrofloxacin. J Exot Pet Med. 15(1):66–69.
   Google Scholar
• Morales DR, Slattery J, Pacurariu A, Pinheiro L, McGettigan P, Kurz X. 2019. Relative and absolute risk of tendon rupture with fluoroquinolone and concomitant fluoroquinolone/corticosteroid therapy: population-based nested case-control study. Clin Drug Investig. 39(2):205–213.
   PubMed Web of Science ®Google Scholar
• Mulgaonkar A, Venitz J, Sweet DH. 2012. Fluoroquinolone disposition: Identification of the contribution of renal secretory and reabsorptive drug transporters. Expert Opin Drug Metab Toxicol. 8(5):553–569.
   PubMed Web of Science ®Google Scholar
• Newkirk KM, Beard LK, Sun X, Ramsay EC. 2017. Investigation of enrofloxacin-associated retinal toxicity in nondomestic felids. J Zoo Wildl Med. 48(2):518–520.
   PubMedGoogle Scholar
• Niedrig D, Maechler S, Hoppe L, Corti N, Kovari H, Russmann S. 2016. Drug safety of macrolide and quinolone antibiotics in a tertiary care hospital: administration of interacting co-medication and QT prolongation. Eur J Clin Pharmacol. 72(7):859–867.
   PubMed Web of Science ®Google Scholar
• Nunes B, Leal C, Rodrigues S, Antunes SC. 2018. Assessment of ecotoxicological effects of ciprofloxacin in Daphnia magna: Life-history traits, biochemical and genotoxic effects. Water Sci Technol. 2017(3):835–844.
   PubMedGoogle Scholar
• Ogino T, Arai T. 2007. Pharmacokinetic interactions of flunixin meglumine and enrofloxacin in ICR mice. Exp Anim. 56(2):79–84.
   PubMedGoogle Scholar
• Orman ES, Conjeevaram HS, Vuppalanchi R, Freston JW, Rochon J, Kleiner DE, Hayashi PH, [DILIN] US Drug-Induced Liver Injury Network Research Group. 2011. Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol. 9(6):517–523.e3.
   PubMed Web of Science ®Google Scholar
• Oyebode OT, Adebiyi OR, Olorunsogo OO. 2019. Toxicity of some broad-spectrum antibacterials in normal rat liver: the role of mitochondrial membrane permeability transition pore. Toxicol Mech Methods. 29(2):128–137.
   PubMed Web of Science ®Google Scholar
• Pallo-Zimmerman LM, Byron JK, Graves TK. 2010. Fluoroquinolones: then and now. Compend Contin Educ Vet. 32(7):E1–E9.
   PubMedGoogle Scholar
• Pan X, Qin P, Liu R, Yu W, Dong X. 2018. Effects of carbon chain length on the perfluoroalkyl acids-induced oxidative stress of erythrocytes in vitro. J Agric Food Chem. 66(25):6414–6420.
   PubMed Web of Science ®Google Scholar
• Papich MG. 2012. Ciprofloxacin pharmacokinetics and oral absorption of generic ciprofloxacin tablets in dogs. Am J Vet Res. 73(7):1085–1091.
   PubMedGoogle Scholar
• Parker RA, Clegg PD, Taylor SE. 2012. The in vitro effects of antibiotics on cell viability and gene expression of equine bone marrow‐derived mesenchymal stromal cells. Equine Vet J. 44(3):355–360.
   PubMedGoogle Scholar
• Pasternak B, Svanström H, Melbye M, Hviid A. 2013. Association between oral fluoroquinolone use and retinal detachment. JAMA. 310(20):2184–2190.
   PubMed Web of Science ®Google Scholar
• Pereira JM, Paiva JA. 2013. Antimicrobial drug interactions in the critically ill patients. Curr Clin Pharmacol. 8(1):25–38.
   PubMedGoogle Scholar
• Persson R, Jick S. 2019. Clinical implications of the association between fluoroquinolones and tendon rupture: The magnitude of the effect with and without corticosteroids. Br J Clin Pharmacol. 85(5):949–959.
   PubMed Web of Science ®Google Scholar
• Piñeiro SA, Cerniglia CE. 2021. Antimicrobial drug residues in animal-derived foods: Potential impact on the human intestinal microbiome. J Vet Pharmacol Ther. 44(2):215–222.
   PubMedGoogle Scholar
• Plhalova L, Zivna D, Bartoskova M, Blahova J, Sevcikova M, Skoric M, Marsalek P, Stancova V, Svobodova Z. 2014. The effects of subchronic exposure to ciprofloxacin on zebrafish (Danio rerio). Neuro Endocrinol Lett. 35(Suppl 2):64–70.
   PubMedGoogle Scholar
• Pomorska-Mól M, Czyżewska-Dors E, Kwit K, Pejsak Z. 2016. Enrofloxacin decreases IL-6 and TNF-α production by lipopolysaccharide-stimulated porcine peripheral blood mononuclear cells. J Vet Res. 60(2):189–193.
   Google Scholar
• Poźniak B, Tikhomirov M, Motykiewicz-Pers K, Bobrek K, Świtała M. 2020. The influence of age and body weight gain on enrofloxacin pharmacokinetics in turkeys-Allometric approach to dose optimization. J Vet Pharmacol Ther. 43(1):67–78.
   PubMed Web of Science ®Google Scholar
• Qin P, Su B, Liu R. 2012. Probing the binding of two fluoroquinolones to lysozyme: A combined spectroscopic and docking study. Mol Biosyst. 8(4):1222–1229.
   PubMedGoogle Scholar
• Qin P, Liu R. 2013. Oxidative stress response of two fluoroquinolones with catalase and erythrocytes: A combined molecular and cellular study. J Hazard Mater. 252-253:321–329.
   PubMed Web of Science ®Google Scholar
• Qin P, Pan X, Liu R, Hu C, Dong Y. 2017a. Toxic interaction mechanism of two fluoroquinolones with serum albumin by spectroscopic and computational methods. J Environ Sci Health B. 52(11):833–841.
   PubMed Web of Science ®Google Scholar
• Qin P, Pan X, Liu R, Qiu J, Fang X. 2017b. Experimental and computational characterization on the binding of two fluoroquinolones to bovine hemoglobin. J Mol Recognit. 30(12):e2647.
   Google Scholar
• Radovanovic M, Dushenkovska T, Cvorovic I, Radovanovic N, Ramasamy V, Milosavljevic K, Surla J, Jecmenica M, Radulovic M, Milovanovic T, et al. 2018. Idiosyncratic drug-induced liver injury due to ciprofloxacin: a report of two cases and review of the literature. Am J Case Rep. 19:1152–1161.
   PubMed Web of Science ®Google Scholar
• Rahal A, Kumar A, Ahmad AH, Malik JK. 2008. Pharmacokinetics of diclofenac and its interaction with enrofloxacin in sheep. Res Vet Sci. 84(3):452–456.
   PubMedGoogle Scholar
• Rajendiran N, Suresh M. 2018. Study of the interaction of ciprofloxacin and sparfloxacin with biomolecules by spectral, electrochemical and molecular docking methods. ILCPA. 78:1–29.
   Google Scholar
• Ramesh M, Sujitha M, Anila PA, Ren Z, Poopal RK. 2021. Responses of Cirrhinus mrigala to second-generation fluoroquinolone (ciprofloxacin) toxicity: Assessment of antioxidants, tissue morphology, and inorganic ions. Environ Toxicol. 36(5):887–902.
   PubMedGoogle Scholar
• Ramirez CJ, Minch JD, Gay JM, Lahmers SM, Guerra DJ, Haldorson GJ, Schneider T, Mealey KL. 2011. Molecular genetic basis for fluoroquinolone-induced retinal degeneration in cats. Pharmacogenet Genomics. 21(2):66–75.
   PubMedGoogle Scholar
• Rasmussen MK. 2020. Porcine cytochrome P450 3A: Current status on expression and regulation. Arch Toxicol. 94(6):1899–1914.
   PubMedGoogle Scholar
• Rawi SM, Mourad IM, Arafa NMS, Alazabi NI. 2011. Effect of ciprofloxacin and levofloxacin on some oxidative stress parameters in brain regions of male albino rats. Afr J Pharm Pharmacol. 5(16):1888–1897.
   Google Scholar
• Rawla P, El Helou ML, Vellipuram AR. 2019. Fluoroquinolones and the risk of aortic aneurysm or aortic dissection: A systematic review and meta-analysis. Cardiovasc Hematol Agents Med Chem. 17(1):3–10.
   PubMedGoogle Scholar
• Ray PD, Huang BW, Tsuji Y. 2012. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal. 24(5):981–990.
   PubMed Web of Science ®Google Scholar
• Redgrave LS, Sutton SB, Webber MA, Piddock LJV. 2014. Fluoroquinolone resistance: Mechanisms, impact on bacteria, and role in evolutionary success. Trends Microbiol. 22(8):438–445.
   PubMed Web of Science ®Google Scholar
• Regmi NL, Abd El-Aty AM, Kuroha M, Nakamura M, Shimoda M. 2005. Inhibitory effect of several fluoroquinolones on hepatic microsomal cytochrome P-450 1A activities in dogs. J Vet Pharmacol Ther. 28(6):553–557.
   PubMedGoogle Scholar
• Regulation (EC) No 470/2009 of the European Parliament and of the Council of 6 May 2009 laying down Community procedures for the establishment of residue limits of pharmacologically active substances in foodstuffs of animal origin, repealing Council Regulation (EEC) No 2377/90 and amending Directive 2001/82/EC of the European Parliament and of the Council and Regulation (EC) No 726/2004 of the European Parliament and of the Council. Off J Eur Union L152, 16.6 2009.
   Google Scholar
• Russo E, Lucatello L, Giovanardi D, Cagnardi P, Ortali G, Di Leva V, Montesissa C. 2012. Approved medication of water with enrofloxacin to treat turkey colibacillosis: Assessment of efficacy using a PK/PD approach. Vet Microbiol. 161(1-2):206–212.
   PubMedGoogle Scholar
• Sadaat SSS, Stankzi N, Tawfeeq MM, Tanin FA, Aziz A, Sasaki K. 2020. Inhibitory effects of several fluoroquinolones on feline CYP1A and 3A in hepatic microsomes. OJVM. 10(12):219–237.
   Google Scholar
• Samarakoon N, Harrisberg B, Ell J. 2007. Ciprofloxacin-induced toxic optic neuropathy. Clin Exp Ophthalmol. 35(1):102–104.
   PubMed Web of Science ®Google Scholar
• San Martin B, Cornejo J, Iragüen D, Hidalgo H, Anadón A. 2007. Depletion study of enrofloxacin and its metabolite ciprofloxacin in edible tissues and feathers of white leghorn hens by liquid chromatography coupled with tandem mass spectrometry. J Food Prot. 70(8):1952–1957.
   PubMed Web of Science ®Google Scholar
• Sang K, Hao H, Huang L, Wang X, Yuan Z. 2015. Pharmacokinetic-Pharmacodynamic Modeling of Enrofloxacin Against Escherichia coli in Broilers. Front Vet Sci. 2:80.
   PubMedGoogle Scholar
• Sansone JM, Wilsman NJ, Leiferman EM, Conway J, Hutson P, Noonan KJ. 2009. The effect of fluoroquinolone antibiotics on growing cartilage in the lamb model. J Pediatr Orthop. 29(2):189–195.
   PubMedGoogle Scholar
• Saraçoğlu A, Temel HE, Ergun B, Colak O. 2009. Oxidative stress-mediated myocardiotoxicity of ciprofloxacin and ofloxacin in juvenile rats. Drug Chem Toxicol. 32(3):238–242.
   PubMed Web of Science ®Google Scholar
• Sarker P, Mily A, Mamun AA, Jalal S, Bergman P, Raqib R, Gudmundsson GH, Agerberth B. 2014. Ciprofloxacin affects host cells by suppressing expression of the endogenous antimicrobial peptides cathelicidins and beta-defensin-3 in colon epithelia. Antibiotics (Basel). 3(3):353–374.
   PubMedGoogle Scholar
• Sasaki K, Shimoda M. 2015. Possible drug-drug interaction in dogs and cats resulted from alteration in drug metabolism: A mini review. J Adv Res. 6(3):383–392.
   PubMed Web of Science ®Google Scholar
• Schmid KL. 2021. Fluoroquinolones are a potent form of chemotherapy. Clin Exp Optom. 104(3):412–416.
   PubMed Web of Science ®Google Scholar
• Scott A, Backman LJ, Speed C. 2015. Tendinopathy: Update on pathophysiology. J Orthop Sports Phys Ther. 45(11):833–841.
   PubMed Web of Science ®Google Scholar
• Seedher N, Agarwal P. 2010. Effect of metal ions on some pharmacologically relevant interactions involving fluoroquinolone antibiotics. Drug Metabol Drug Interact. 25(1-4):17–24.
   PubMedGoogle Scholar
• Sehonova P, Tokanova N, Hodkovicova N, Kroupova HK, Tumova J, Blahova J, Marsalek P, Plhalova L, Doubkova V, Dobsikova R, et al. 2019. Oxidative stress induced by fluoroquinolone enrofloxacin in zebrafish (Danio rerio) can be ameliorated after a prolonged exposure. Environ Toxicol Pharmacol. 67:87–93.
   PubMed Web of Science ®Google Scholar
• Sendzik J, Shakibaei M, Schäfer-Korting M, Lode H, Stahlmann R. 2010. Synergistic effects of dexamethasone and quinolones on human-derived tendon cells. Int J Antimicrob Agents. 35(4):366–374.
   PubMed Web of Science ®Google Scholar
• Seo KW, Holt R, Jung YS, Rodriguez CO, Jr, Chen X, Rebhun RB. 2012. Fluoroquinolone-mediated inhibition of cell growth, S-G2/M cell cycle arrest, and apoptosis in canine osteosarcoma cell lines. PLoS One. 7(8):e42960.
   PubMedGoogle Scholar
• Shaki F, Ashari S, Ahangar N. 2016. Melatonin can attenuate ciprofloxacin induced nephrotoxicity: Involvement of nitric oxide and TNF-α. Biomed Pharmacother. 84:1172–1178.
   PubMed Web of Science ®Google Scholar
• Shahzadi A, Javed I, Aslam B, Muhammad F, Asi MR, Ashraf MY, Zia-Ur-Rahman A. 2011. Therapeutic effects of ciprofloxacin on the pharmacokinetics of carbamazepine in healthy adult male volunteers. Pak J Pharm Sci. 24(1):63–68.
   PubMedGoogle Scholar
• Shirsat S, Kadam A, Mane RS, Jadhav VV, Zate MK, Naushad M, Kim KH. 2016. Protective role of biogenic selenium nanoparticles in immunological and oxidative stress generated by enrofloxacin in broiler chicken. Dalton Trans. 45(21):8845–8853.
   PubMedGoogle Scholar
• Siengdee P, Euppayo T, Buddhachat K, Chomdej S, Nganvongpanit K. 2016. Two fluoroquinolones and their combinations with hyaluronan: comparison of effects on canine chondrocyte culture. J Vet Pharmacol Ther. 39(5):439–451.
   PubMedGoogle Scholar
• Simon Z, Katja B, Darko U, Marjan V, Albin K. 2010. Metal cation-fluoroquinolone complexes do not permeate through the intestinal absorption barrier. J Pharm Biomed Anal. 53(3):655–659.
   PubMedGoogle Scholar
• Slana M, Pahor V, Cvitkovič Maričič L, Sollner-Dolenc M. 2014. Excretion pattern of enrofloxacin after oral treatment of chicken broilers. J Vet Pharmacol Ther. 37(6):611–614.
   PubMedGoogle Scholar
• Smith EM, Iftikar FI, Higgins S, Irshad A, Jandoc R, Lee M, Wilson JY. 2012. In vitro inhibition of cytochrome P450-mediated reactions by gemfibrozil, erythromycin, ciprofloxacin and fluoxetine in fish liver microsomes. Aquat Toxicol. 109:259–266.
   PubMed Web of Science ®Google Scholar
• Sousa J, Alves G, Fortuna A, Falcão A. 2014. Third and fourth generation fluoroquinolone antibacterials: a systematic review of safety and toxicity profiles. Curr Drug Saf. 9(2):89–105.
   PubMedGoogle Scholar
• Sriwiriyajan S, Samaeng M, Ridtitid W, Mahatthanatrakul W, Wongnawa M. 2011. Pharmacokinetic interactions between ciprofloxacin and itraconazole in healthy male volunteers. Biopharm Drug Dispos. 32(3):168–174.
   PubMed Web of Science ®Google Scholar
• Stahlmann R. 2002. Clinical toxicological aspects of fluoroquinolones. Toxicol Lett. 127(1-3):269–277.
   PubMed Web of Science ®Google Scholar
• Stahlmann R, Lode H. 2010. Safety considerations of fluoroquinolones in the elderly: An update. Drugs Aging. 27(3):193–209.
   PubMed Web of Science ®Google Scholar
• Stahlmann R, Lode HM. 2013. Risks associated with the therapeutic use of fluoroquinolones. Expert Opin Drug Saf. 12(4):497–505.
   PubMed Web of Science ®Google Scholar
• Stojković A, Tajber L, Paluch KJ, Djurić Z, Parojčić J, Corrigan OI. 2014. Biopharmaceutical characterisation of ciprofloxacin-metallic ion interactions: Comparative study into the effect of aluminium, calcium, zinc and iron on drug solubility and dissolution. Acta Pharm. 64(1):77–88.
   PubMedGoogle Scholar
• Strzępa A, Majewska-Szczepanik M, Kowalczyk P, Woźniak D, Motyl S, Szczepanik M. 2016. Oral treatment with enrofloxacin early in life promotes Th2-mediated immune response in mice. Pharmacol Rep. 68(1):44–50.
   PubMedGoogle Scholar
• Sureshkumar V, Sarathchandra G, Ramesh J. 2013. Effect of enrofloxacin on zootechnical performance, behaviour and immunohistopathological response in broiler chicken. Vet World. 6(6):337–342.
   Google Scholar
• Szałek E, Karbownik A, Grabowski T, Sobańska K, Wolc A, Grześkowiak E. 2013. Pharmacokinetics of sunitinib in combination with fluoroquinolones in rabbit model. Pharmacol Rep. 65(5):1383–1390.
   PubMedGoogle Scholar
• Talla V, Veerareddy PR. 2011. Oxidative stress induced by fluoroquinolones on treatment for complicated urinary tract infections in Indian patients. J Young Pharm. 3(4):304–309.
   PubMedGoogle Scholar
• Tan BL, Norhaizan ME, Liew WPP, Rahman HS. 2018. Antioxidant and oxidative stress: A mutual interplay in age-related diseases. Front Pharmacol. 9(1162):1162.
   PubMedGoogle Scholar
• Tannenbaum C, Sheehan NL. 2014. Understanding and preventing drug-drug and drug-gene interactions. Expert Rev Clin Pharmacol. 7(4):533–544.
   PubMed Web of Science ®Google Scholar
• Taslidere E, Dogan Z, Elbe H, Vardi N, Cetin A, Turkoz Y. 2016. Quercetin protection against ciprofloxacin induced liver damage in rats. Biotech Histochem. 91(2):116–121.
   PubMed Web of Science ®Google Scholar
• Thai T, Salisbury BH, Zito PM. 2021. Ciprofloxacin. Treasure Island (FL): StatPearls Publishing.
   Google Scholar
• Thompson AM. 2007. Ocular toxicity of fluoroquinolones. Clin Exp Ophthalmol. 35(6):566–577.
   PubMed Web of Science ®Google Scholar
• Tirumala-Echampati K, Roberts DM. 2018. Communication and ciprofloxacin-associated acute kidney injury. Aust Prescr. 41(4):122.
   PubMedGoogle Scholar
• Trouchon T, Lefebvre S. 2016. A review of enrofloxacin for veterinary use. OJVM. 06 (02):40–58.
   Google Scholar
• Tsai WC, Yang YM. 2011. Fluoroquinolone-associated tendinopathy. Chang Gung Med J. 34(5):461–467.
   PubMedGoogle Scholar
• Tsai WC, Hsu CC, Chen CPC, Chang HN, Wong AMK, Lin MS, Pang JHS. 2011. Ciprofloxacin up-regulates tendon cells to express matrix metalloproteinase-2 with degradation of type I collagen. J Orthop Res. 29(1):67–73.
   PubMed Web of Science ®Google Scholar
• Unger C, Al-Jashaami LS. 2016. Ciprofloxacin exposure leading to fatal hepatotoxicity: An unusual correlation. Am J Case Rep. 17:676–681.
   PubMedGoogle Scholar
• Vaccaro E, Giorgi M, Longo V, Mengozzi G, Gervasi PG. 2003. Inhibition of cytochrome P450 enzymes by enrofloxacin in the sea bass (Dicentrarchus labrax). Aquat Toxicol. 62(1):27–33.
   PubMed Web of Science ®Google Scholar
• Wang H, Che B, Duan A, Mao J, Dahlgren RA, Zhang M, Zhang H, Zeng A, Wang X. 2014. Toxicity evaluation of β-diketone antibiotics on the development of embryo-larval zebrafish (Danio rerio). Environ Toxicol. 29(10):1134–1146.
   PubMedGoogle Scholar
• Wang N, Nkejabega N, Hien NN, Huynh TT, Silvestre F, Phuong NT, Danyi S, Widart J, Douny C, Scippo ML, Kestemont P, et al. 2009. Adverse effects of enrofloxacin when associated with environmental stress in tra catfish (Pangasianodon hypophthalmus). Chemosphere. 77(11):1577–1584.
   PubMed Web of Science ®Google Scholar
• Wang J, Hao H, Huang L, Liu Z, Chen D, Yuan Z. 2016. Pharmacokinetic and pharmacodynamic integration and modeling of enrofloxacin in swine for Escherichia coli. Front Microbiol. 7:36.
   PubMedGoogle Scholar
• Wanyu L, Bekele TG, Hongxia Z. 2020. Metabolism of enrofloxacin in liver microsomes of crucian carp (Carassius auratus) and its key enzymes in vitro. Asian J Ecotox. 15(3):64–70.
   Google Scholar
• Weese JS, Blondeau JM, Boothe D, Breitschwerdt EB, Guardabassi L, Hillier A, Lloyd DH, Papich MG, Rankin SC, Turnidge JD, et al. 2011. Antimicrobial use guidelines for treatment of urinary tract disease in dogs and cats: antimicrobial guidelines working group of the international society for companion animal infectious diseases. Vet Med Int. 2011:263768.
   PubMedGoogle Scholar
• WHO (World Health Organization). 2017. Critically important antimicrobials for human medicine: ranking of antimicrobial agents for risk management of antimicrobial resistance due to non-human use, 5th rev. Geneva: World Health Organization.
   Google Scholar
• WHO (World Health Organization). 2019. Critically important antimicrobials for human medicine, 6th rev. Geneva: World Health Organization.
   Google Scholar
• Wise BL, Peloquin C, Choi H, Lane NE, Zhang Y. 2012. Impact of age, sex, obesity, and steroid use on quinolone-associated tendon disorders. Am J Med. 125(12):1228.e23–1228.e28.
   PubMed Web of Science ®Google Scholar
• Xiao X, Jiang L, Lan W, Jiang Y, Wang Z. 2018. In vivo pharmacokinetic/Pharmacodynamic modeling of Enrofloxacin against Escherichia coli in broiler chickens. BMC Vet Res. 14(1):374.
   PubMedGoogle Scholar
• Xu L, Wang H, Yang X, Lu L. 2013. Integrated pharmacokinetics/pharmacodynamics parameters-based dosing guidelines of enrofloxacin in grass carp Ctenopharyngodon idella to minimize selection of drug resistance. BMC Vet Res. 9:126.
   PubMed Web of Science ®Google Scholar
• Xu Y-H, Wei X-L, Xu Y-C, Zhang D-G, Zhao T, Zheng H, Luo Z. 2021. Waterborne enrofloxacin exposure activated oxidative stress and MAPK pathway, induced apoptosis and resulted in immune dysfunction in the gills of yellow catfish Pelteobagrus fulvidraco. Aquaculture. 547:737541.
   Google Scholar
• Xu X, Lu Q, Yang Y, Martínez MA, Lopez-Torres B, Martínez-Larrañaga MR, Wang X, Anadón A, Ares I. 2021. A proposed “steric-like effect” for the slowdown of enrofloxacin antibiotic metabolism by ciprofloxacin, and its mechanism. Chemosphere. 284:131347.
   PubMedGoogle Scholar
• Yahia R, Masoud MA, Sheded MS, Mansour HA. 2020. The possible neurobehavioral protective effects of natural antioxidant against phototoxicity attenuation of antimicrobial quinolone group in rats. J Biochem Mol Toxicol. 34(7):e22495.
   PubMedGoogle Scholar
• Yamarik TA, Wilson WD, Wiebe VJ, Pusterla N, Edman J, Papich MG. 2010. Pharmacokinetics and toxicity of ciprofloxacin in adult horses. J Vet Pharmacol Ther. 33(6):587–594.
   PubMedGoogle Scholar
• Yang C, Song G, Lim W. 2020a. A review of the toxicity in fish exposed to antibiotics. Comp Biochem Physiol C Toxicol Pharmacol. 237:108840.
   PubMedGoogle Scholar
• Yang X, Li Y, Wang X. 2020b. Effects of ciprofloxacin exposure on the earthworm Eisenia fetida. Environ Pollut. 262:114287.
   PubMedGoogle Scholar
• Yang HY, Guo DH, Jia WP, Zhu M, Xu YJ, Wang XY. 2019. Incidence, clinical features, and risk factors of fluoroquinolone-induced acute liver injury: a case-control study. Ther Clin Risk Manag. 15:389–395.
   PubMed Web of Science ®Google Scholar
• Yi H, Shin MJ, Cho SM, Lee DG, Cho K, Cho HJ, Shin SJ, Bartlett MG, Kim JS, Shin HC. 2010. Nonlinear toxicokinetics of enrofloxacin in rats. Arch Pharm Res. 33(11):1851–1857.
   PubMedGoogle Scholar
• Yoon JH, Brooks RL, Jr, Khan A, Pan H, Bryan J, Zhang J, Budsberg SC, Mueller POE, Halper J. 2004a. The effect of enrofloxacin on cell proliferation and proteoglycans in horse tendon cells. Cell Biol Toxicol. 20(1):41–54.
   PubMed Web of Science ®Google Scholar
• Yoon JH, Brooks RL, Jr, Zhao JZ, Isaacs D, Halper J. 2004b. The effects of enrofloxacin on decorin and glycosaminoglycans in avian tendon cell cultures. Arch Toxicol. 78(10):599–608.
   PubMed Web of Science ®Google Scholar
• Yu X, Jiang DS, Wang J, Wang R, Chen T, Wang K, Cao S, Wei X. 2019. Fluoroquinolone use and the risk of collagen-associated adverse events: A systematic review and meta-analysis. Drug Saf. 42(9):1025–1033.
   PubMed Web of Science ®Google Scholar
• Zaccaroni A, Perez-Lopez M, de la Casa Resino I, Medri G, Ceneri F, Bertini S, Mordenti O, Cortinovis L, Sirri R, Mandrioli L. 2017. Short communication: Alteration in blood parameters by enrofloxacin in juvenile lesser spotted dogfish (Scyliorhinus canicula, Linnaeus, 1758) after intramuscular injection. Res Vet Sci. 113:1–4.
   PubMedGoogle Scholar
• Zanger UM, Schwab M. 2013. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 138(1):103–141.
   PubMed Web of Science ®Google Scholar
• Zhang LL, Zhang JR, Guo K, Ji H, Zhang Y, Jiang SX. 2011. Effects of fluoroquinolones on CYP4501A and 3A in male broilers. Res Vet Sci. 90(1):99–105.
   PubMedGoogle Scholar
• Zhang GF, Liu X, Zhang S, Pan B, Liu ML. 2018a. Ciprofloxacin derivatives and their antibacterial activities. Eur J Med Chem. 146:599–612.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Huang J, Liu Y, Guo T, Wang L. 2018b. Using the lentiviral vector system to stably express chicken P-gp and BCRP in MDCK cells for screening the substrates and studying the interplay of both transporters. Arch Toxicol. 92(6):2027–2042.
   PubMedGoogle Scholar
• Zhang Y, Wang L, Zhuang H, Li X, Gao X, An Z, Liu X, Yang H, Wei W, Zhang X. 2019. Excessive use of enrofloxacin leads to growth inhibition of juvenile giant freshwater prawn Macrobrachium rosenbergii. Ecotoxicol Environ Saf. 169:344–352.
   PubMedGoogle Scholar
• Zheng M, Liu X, Xu Y, Li H, Luo C, Jiang H. 2013. Computational methods for drug design and discovery: Focus on China. Trends Pharmacol Sci. 34(10):549–559.
   PubMed Web of Science ®Google Scholar
• Zobeiri F, Sadrkhanlou RA, Salami S, Mardani K. 2013. Long-term effect of ciprofloxacin on testicular tissue: Evidence for biochemical and histochemical changes. Int J Fertil Steril. 6(4):294–303.
   PubMedGoogle Scholar